Literature DB >> 11123429

Synergistic suppressive effect of double transfection of tumor necrosis factor-alpha and interleukin 12 genes on tumorigenicity of Meth-A cells.

H Fujiwara1, N Yamauchi, Y Sato, K Sasaki, M Takahashi, T Okamoto, T Sato, S Iyama, Y Koshita, M Hirayama, H Yamagishi, Y Niitsu.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) and interleukin 12 (IL-12), both potent antitumor cytokines, are known to be involved in the host's antitumor immune surveillance in tumor bearers, via different mechanisms. The former enhances the activities of dendritic cells, natural killer / lymphocyte-activated killer (NK / LAK) and cytotoxic T lymphocyte (CTL), while the latter induces Th1-type cellular immunity and enhances the activities of natural killer T (NKT), NK / LAK and CTL. In the present study, in the expectation of synergistic actions of these cytokines in stimulating the host's immune responses, we investigated the feasibility of a cancer vaccine involving double transfection with both genes in a murine model. The expression of major histocompatibility complex (MHC) class I, class II and B7.1 on the surface of the double transfectants was enhanced as revealed by FACS analysis. A significant decrease in tumorigenicity was observed in mice inoculated with the double transfectants. Cytotoxicity assay revealed that the activities of NK / LAK and CTL from spleens of mice bearing the double transfectants were enhanced. The induction of tumor-specific immunity was confirmed by rechallenge with parental Meth-A cells in mice that had rejected the double transfectants. Thus, double transfection of TNF-alpha and IL-12 genes was considered to bring about synergistic suppressive effects on the tumorigenicity of transfectants through the activation of killer cells by produced cytokines and the enhancement of expression of MHC class I, II and B7.1 molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123429      PMCID: PMC5926296          DOI: 10.1111/j.1349-7006.2000.tb00917.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

1.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors.

Authors:  A J Korman; J D Frantz; J L Strominger; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages.

Authors:  P Allavena; L Piemonti; D Longoni; S Bernasconi; A Stoppacciaro; L Ruco; A Mantovani
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

4.  Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling.

Authors:  B Koppelman; J J Neefjes; J E de Vries; R de Waal Malefyt
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

5.  Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor.

Authors:  Y Koshita; Y Lu; S Fujii; H Neda; T Matsuyama; Y Satoh; Y Itoh; M Takahashi; J Kato; S Sakamaki
Journal:  Int J Cancer       Date:  1995-09-27       Impact factor: 7.396

6.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.

Authors:  Y Noguchi; E C Richards; Y T Chen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

7.  Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen.

Authors:  M A Fassanito; D Loftus; R M De Leo; L W Law; E Appella; A B De Leo
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

8.  Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor.

Authors:  T Himeno; N Watanabe; N Yamauchi; M Maeda; Y Tsuji; T Okamoto; H Neda; Y Niitsu
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

9.  Effects of IL-12 on helper T cell-dependent immune responses in vivo.

Authors:  A J McKnight; G J Zimmer; I Fogelman; S F Wolf; A K Abbas
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  2 in total

1.  Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines.

Authors:  Ning-Ling Ge; Sheng-Long Ye; Ning Zheng; Rui-Xia Sun; Yin-Kun Liu; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

2.  Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.

Authors:  Randall S MacGill; Thomas A Davis; Jennifer Macko; Helena J Mauceri; Ralph R Weichselbaum; C Richter King
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 5.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.